Read the newsletter by clicking here.
The year 2016 has been both intensive and exciting and during which Xintela has experienced strong growth. Together with our current progress in regenerative medicine and cancer, we have also strengthened the company’s structure and resources. We conducted an oversubscribed rights issue and listed the company on Nasdaq First North, in addition to making several recruitments within the clinical development, business development and commercialisation functions.
We plan a more extensive update in January on the company’s milestones in the different development projects, including the on-going equine study that focuses on determining whether our stem cells are safe to use. Once again, we visited the group at Cornell University, Ithaca, New York, and confirmed that the analyses from the study are on their way to completion and which we can report on soon.
In this newsletter we continue our film interview series, this time with Xintela’s well respected Board Member, Karin Wingstrand. We also report on interesting external scientific data that support our own research into cancer. Happy reading in December darkness!
CEO, Xintela AB.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO